Market Place
Sourcing Support
Bayer Sues Moderna, J&J And Pfizer/Biontech Over COVID Vax Tech
08 Jan 2026 //
FIERCE PHARMA
Lilly, J&J Top Clarivate`s 2026 Drugs to Watch
07 Jan 2026 //
FIERCE PHARMA
J&J Seeks FDA Clearance for OTTAVA Robotic Surgical System
07 Jan 2026 //
BUSINESSWIRE
J&J`s Tremfya Closes Out 2025 As December`s Top TV Ad Spender
06 Jan 2026 //
FIERCE PHARMA
Johnson & Johnson Declares Q1 2026 Dividend
02 Jan 2026 //
BUSINESSWIRE
Johnson & Johnson Completes Acquisition of Halda Therapeutics
29 Dec 2025 //
BUSINESSWIRE
J&J Halts Mid-stage Trial of Experimental Eczema Drug
27 Dec 2025 //
REUTERS
J&J vows appeal after US jury hits it with record $1.5B talc
27 Dec 2025 //
REUTERS
Europe Greenlights TREMFYA For Pediatric Plaque Psoriasis
19 Dec 2025 //
PHARMIWEB
Minnesota Jury Awards $65.5M vs. Johnson & Johnson
19 Dec 2025 //
BUSINESSWIRE
FDA Approves RYBREVANT + LAZCLUZE for Shortest First-Line Dosing
17 Dec 2025 //
PR NEWSWIRE
Janssen’s Biologics Rybrevant Faspro Receives Approval in US
17 Dec 2025 //
FDA
Link Cell Therapies Launches CAR-T for Solid, Liquid Tumors
15 Dec 2025 //
PR NEWSWIRE
Johnson & Johnson Hosts Investor Call On Q4 Results
15 Dec 2025 //
BUSINESSWIRE
FDA `Proactively` Awards J&J A National Priority Review Voucher
15 Dec 2025 //
FIERCE PHARMA
FDA Approves AKEEGA For BRCA2-Mutated Prostate Cancer
12 Dec 2025 //
PR NEWSWIRE
Majestec-3 Study Backs TECVAYLI With DARZALEX FASPRO
09 Dec 2025 //
PR NEWSWIRE
NHS Scotland Approves RYBREVANT for EGFR+ NSCLC
09 Dec 2025 //
PHARMIWEB
ASH: J&J Pressures CAR-T With Tecvayli Combo In 2L Myeloma
09 Dec 2025 //
FIERCE PHARMA
Carvykti Shows Durable Remissions in Relapsed Multiple Myeloma
06 Dec 2025 //
GLOBENEWSWIRE
Johnson & Johnson`s INLEXZO Shows 74% Disease-Free Survival
05 Dec 2025 //
PR NEWSWIRE
Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau
05 Dec 2025 //
BIOSPACE
FDA Panel Votes Against J&J Shunt Implant For Heart Failure
05 Dec 2025 //
FIERCE BIOTECH
J&J Directs A New Campaign With Naomi Watts In The Spotlight
03 Dec 2025 //
FIERCE PHARMA
J&J Wins EU Approval for IMAAVY in Generalized Myasthenia Gravis
01 Dec 2025 //
GLOBENEWSWIRE
ASH25: J&J`s Tecvayli, Darzalex Data May Shift Myeloma Paradigm
25 Nov 2025 //
BIOSPACE
J&J`s Anti-Tau Antibody Posdinemab Flops In Phase 2
24 Nov 2025 //
FIERCE BIOTECH
J&J discontinues Alzheimer`s study of tau-targeting antibody
21 Nov 2025 //
PRESS RELEASE
Contineum-J&J drug fails to improve vision in ph. 2 MS trial
20 Nov 2025 //
BUSINESSWIRE
Merus, Halozyme Sign Global Pact to Develop Petosemtamab
17 Nov 2025 //
PR NEWSWIRE
New Long-Term Data Reinforces TREMFYA Blocking Joint Damage
17 Nov 2025 //
PR NEWSWIRE
Halda Therapeutics Announces Acquisition By Johnson & Johnson
17 Nov 2025 //
PRESS RELEASE
Update On Phase 3 Librexia ACS Trial
15 Nov 2025 //
BUSINESSWIRE
J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
12 Nov 2025 //
FIERCE PHARMA
EXoPERT Joins JLABS TMC, J&J`s Global Incubator Network
11 Nov 2025 //
PR NEWSWIRE
J&J Survey Underscores The Power Of Patient Community In IBD
07 Nov 2025 //
FIERCE PHARMA
Samsung Bioepis Settles Pyzchiva (Ustekinumab) in Europe
06 Nov 2025 //
BUSINESS WIRE
FDA Approval of Caplyta for Major Depressive Disorder
06 Nov 2025 //
PR NEWSWIRE
J&J Secures First Expansion For Leading Cancer Drug
06 Nov 2025 //
PR NEWSWIRE
Johnson & Johnson Joins Citi`s 2025 Global Healthcare Conference
05 Nov 2025 //
BUSINESSWIRE
Nanobiotix Finds New Way to Source Cash from J&J-Partnered Drug
31 Oct 2025 //
FIERCE BIOTECH
J&J Launches IMAAVY Head-to-Head Study in gMG at AANEM 2025
29 Oct 2025 //
PR NEWSWIRE
Texas AG Sues Kenvue Over Alleged Tylenol-Autism Link
28 Oct 2025 //
FIERCE PHARMA
Tremfya Shows Long-Term Remission in Crohn`s Disease
27 Oct 2025 //
PR NEWSWIRE
Icotrokinra Shows 28-Week Efficacy, Safety in Ulcerative Colitis
27 Oct 2025 //
PR NEWSWIRE
TREMFYA® (Guselkumab) Approved By European Commission
25 Oct 2025 //
GLOBENEWSWIRE
Icotrokinra Shows Durable Skin Clearance in Psoriasis Patients
24 Oct 2025 //
PR NEWSWIRE
Nipocalimab Reduces Sjögren`s Disease Activity In The Lancet
24 Oct 2025 //
PR NEWSWIRE
Nanobiotix Transfers Ph3 H&N Cancer Trial to JNJ-1900 Program
24 Oct 2025 //
GLOBENEWSWIRE
Johnson & Johnson Joins 7Th Wolfe Research Healthcare Conference
22 Oct 2025 //
BUSINESSWIRE
How J&J Kept Growing Amid The Erosion Of Cornerstone Drug Stelara
22 Oct 2025 //
BIOSPACE
Johnson & Johnson`s Rybrevant Shows 45% Response Rate In HNSCC
22 Oct 2025 //
INDPHARMAPOST
J&J Signs On As The New York Jets` Medical Innovation Sponsor
22 Oct 2025 //
FIERCE PHARMA
Tecvayli + Darzalex Faspro Improve PFS & OS vs Standard Care
16 Oct 2025 //
PR NEWSWIRE
J&J Eyes Earlier Myeloma Treatment With Ph. 3 Tecvayli Combo Win
16 Oct 2025 //
FIERCE PHARMA
J&J Faces First UK Lawsuits Over Baby Powder Cancer Link
15 Oct 2025 //
REUTERS
Johnson & Johnson Boosts 2025 Sales Forecast After Q3 Results
14 Oct 2025 //
BUSINESSWIRE
Johnson & Johnson Declares Q4 2025 Dividend
14 Oct 2025 //
BUSINESSWIRE
J&J Chief Duato `Optimistic` Amid MFN Discussions With Trump
14 Oct 2025 //
FIERCE PHARMA
J&J Reveals Plan To Spin Off Its $9B Orthopedics Business
14 Oct 2025 //
FIERCE BIOTECH
